Dasatinib In Waldenström Macroglobulinemia

Phase 1 Terminated 3 enrolled Jorge J. Castillo, MD Bristol-Myers Squibb · collab

NaSingle-groupOpen-labelTreatment

Summary

This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations

Timeline

Start: 2019-11-04
Primary completion: 2021-12-31
Completion: 2021-12-31

Publications

Castillo JJ, Sarosiek S, Flynn CA, Leventoff C, Little M, White T, Meid K, Treon SP. A pilot study on dasatinib in patients with Waldenstrom macroglobulinemia progressing on ibrutinib. EJHaem. 2022 Jun 7;3(3):927-929. doi: 10.1002/jha2.493. eCollection 2022 Aug.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	100 mg	Oral

Dasatinib In Waldenström Macroglobulinemia

Summary

Timeline

Publications

Drugs

Indications